DrugPatentWatch Database Preview
Pharmacyclics Inc Company Profile
What is the competitive landscape for PHARMACYCLICS INC, and when can generic versions of PHARMACYCLICS INC drugs launch?
PHARMACYCLICS INC has two approved drugs.
There are twenty-seven US patents protecting PHARMACYCLICS INC drugs.
Summary for Pharmacyclics Inc
| US Patents: | 27 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 2 |
Drugs and US Patents for Pharmacyclics Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-002 | Feb 16, 2018 | RX | Yes | No | 7,514,444 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-004 | Feb 16, 2018 | RX | Yes | Yes | 9,655,857 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-003 | Feb 16, 2018 | RX | Yes | No | 8,957,079 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | CAPSULE;ORAL | 205552-001 | Nov 13, 2013 | RX | Yes | Yes | 8,008,309 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-002 | Feb 16, 2018 | RX | Yes | No | 9,801,883 | ➤ Sign Up | ➤ Sign Up | ||||
| Pharmacyclics Inc | IMBRUVICA | ibrutinib | TABLET;ORAL | 210563-004 | Feb 16, 2018 | RX | Yes | Yes | 9,801,881 | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for Pharmacyclics Inc Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Lithuania | 2526771 | ➤ Sign Up |
| Taiwan | 201402122 | ➤ Sign Up |
| Brazil | PI0622054 | ➤ Sign Up |
| Poland | 2081435 | ➤ Sign Up |
| New Zealand | 717373 | ➤ Sign Up |
| Hungary | E028086 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Pharmacyclics Inc Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2015017 | Lithuania | ➤ Sign Up | PRODUCT NAME: IBRUTINIBUM; REGISTRATION NO/DATE: EU/1/14/945 20141021 |
| 2016034 | Lithuania | ➤ Sign Up | PRODUCT NAME: IBRUTINIBAS ARBA FARMACISKAI PRIIMTINA JO DRUSKA; REGISTRATION NO/DATE: EU/1/14/945 C(2016)3293 20160526 |
| 321 | Luxembourg | ➤ Sign Up | PRODUCT NAME: INHIBITEURS DE LA TYROSINE KINASE DE BRUTON |
| 2017009 | Lithuania | ➤ Sign Up | PRODUCT NAME: IBRUTINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/14/945 C(2015)4704 20170703 |
| 2017 00012 | Denmark | ➤ Sign Up | PRODUCT NAME: IBRUTINIB, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 C(2015)4704 20150707 |
| 0728 | Netherlands | ➤ Sign Up | DETAILS ASSIGNMENT: VERANDERING VAN EIGENAAR(S), SAMENVOEGEN |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
